Xiangman
Zou
ab,
Zhi
Liu
bc,
Liya
Liu
b,
Wei
Shi
b,
Wanzhen
Li
bc,
Zifen
Guo
*a,
Feng
Tang
*b and
Wei
Huang
*bde
aInstitute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, Hunan 421001, China. E-mail: guozifen76@163.com
bCAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, P. R. China. E-mail: tangfeng2013@simm.ac.cn
cSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, 210023, Nanjing, China
dUniversity of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China
eSchool of Pharmaceutical Science and Technology, Hangzhou, Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, P. R. China. E-mail: huangwei@simm.ac.cn
First published on 7th July 2022
Correction for ‘Enhanced transglycosylation activity of an Endo-F3 mutant by ligand-directed localization’ by Xiangman Zou et al., Org. Biomol. Chem., 2022, 20, 3086–3095, https://doi.org/10.1039/D2OB00030J.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (NSFC, no. 21877116, and 82003574), the Shanghai Municipal Science and Technology Major Project (the Shanghai Sail Program, no. 19YF1457100), the Special Research Assistant Program (Chinese Academy of Sciences, CAS), the National Key Research and Development Plan (no. 2021YFE0200500), and the Key Project of the Education Department of Hunan Province (no. 19A419).
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry 2022 |